ArticleAnnals of translational medicine2015
Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.
Article in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Hair Follicle Stem Cells: Emerging Physiology and Therapeutic Applications.Stem cell reviews and reports · 2026Review
- Topical ruxolitinib ± oral baricitinib in the treatment of active non-segmental vitiligo: A retrospective analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Evaluation of Melanocytes and T-cells in Vitiliginous Skin Pre- and Post-Narrow-Band UVB Phototherapy.Indian dermatology online journal · 2026Article
- Design, synthesis, and activity study of heterocyclic derivatives as JAK inhibitors.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with anFrontiers in immunology · 2026Article
- Integrative Multi-Omics and Experimental Analyses Identify TAPBP as a Key Mediator Linking Genetic Susceptibility to Melanocyte Dysfunction in Vitiligo.Clinical, cosmetic and investigational dermatology · 2026Article
- JAK Activation Drives MED15-Associated Melanocyte Dysfunction in Vitiligo Beyond Immune Cells.Clinical, cosmetic and investigational dermatology · 2026Article
- Oxidative stress in refractory and recurrent vitiligo: from immune amplification mechanisms to potential stratified antioxidant combination therapy.Frontiers in immunology · 2026Review
- Serum Granulysin Levels in Vitiligo and Alopecia Areata: A Potential Biomarker for Disease Activity and Dermoscopic Evaluation.Journal of clinical medicine · 2025Article
- Comprehensive Overview of Cytokine Interplay in Vitiligo: A Decade of Meta-Analyses Systematically Reviewed.Life (Basel, Switzerland) · 2025Review
- Emerging Therapeutic Innovations for Vitiligo Treatment.Current issues in molecular biology · 2025Review
- Vitiligo: are microbes to blame?Bioscience of microbiota, food and health · 2025Review
- HPMC-Zein Film-forming Gel Loaded with 5-Fluorouracil Coupled with COAAPS PharmSciTech · 2024Article
- Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications.Journal of clinical medicine · 2024Review
- Up-and-Coming Drugs for the Treatment of Vitiligo.Annals of dermatology · 2024Review
- Advances in research on immunocyte iron metabolism, ferroptosis, and their regulatory roles in autoimmune and autoinflammatory diseases.Cell death & disease · 2024Review
- Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year.American journal of clinical dermatology · 2024Article
- Modulation of CXCL10 activity as a therapeutic target of ocular toxoplasmosis in diabetic mice.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Polyphenols targeting multiple molecular targets and pathways for the treatment of vitiligo.Frontiers in immunology · 2024Review
- A Bioinformatic Study on the Potential Anti-Vitiligo Activity of aMolecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.